Impact of new molecular criteria on diagnosis and survival of adult glioma patients.
DNA methylation profiling
Next-generation sequencing
Retrospective reclassification
TERT promoter mutation
WHO-CNS5
cIMPACT-NOW
Journal
IBRO neuroscience reports
ISSN: 2667-2421
Titre abrégé: IBRO Neurosci Rep
Pays: Netherlands
ID NLM: 101775148
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
26
05
2022
accepted:
17
09
2022
entrez:
7
10
2022
pubmed:
8
10
2022
medline:
8
10
2022
Statut:
epublish
Résumé
The fifth edition WHO classification of Tumors of the Central nervous system (WHO-CNS5) integrated new molecular parameters to refine CNS tumor classification. This study aimed to reclassify a retrospective cohort of adult glioma patients according to WHO-CNS5, and assess if overall survival (OS) correlated with the revised diagnosis. Further, the diagnostic impact of methylation profiling (MP) was evaluated. Adult gliomas diagnosed according to 2016 WHO-CNS (n = 226) were evaluated according to WHO-CNS5 criteria. All patients had diagnostic NGS performed. 29 patients had 850k MP performed due to challenging tumor cases. OS was analyzed using Kaplan-Meier plots and log-rank test. 19 patients were reclassified. Specifically, diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma (DAG-G) were reclassified as glioblastoma (n = 15). Shifts to glioblastoma were because of
Identifiants
pubmed: 36204252
doi: 10.1016/j.ibneur.2022.09.005
pii: S2667-2421(22)00067-7
pmc: PMC9529576
doi:
Types de publication
Journal Article
Langues
eng
Pagination
299-305Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Brain Pathol. 2017 Mar;27(2):146-159
pubmed: 26919320
Cancer. 1989 Jul 15;64(2):442-7
pubmed: 2736491
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Neurooncol Adv. 2020 Sep 18;2(1):vdaa126
pubmed: 33235995
J Mol Diagn. 2016 Sep;18(5):775-786
pubmed: 27461031
Neuro Oncol. 2022 Apr 1;24(4):571-581
pubmed: 34555175
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
Brain Tumor Pathol. 2019 Apr;36(2):84-91
pubmed: 30937703
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Niger Med J. 2013 Mar;54(2):79-86
pubmed: 23798791
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Acta Neuropathol. 2018 Aug;136(2):181-210
pubmed: 29967940
Acta Neuropathol. 2010 Sep;120(3):297-304
pubmed: 20644945
Acta Neuropathol Commun. 2019 Feb 20;7(1):24
pubmed: 30786920
N Engl J Med. 2000 Nov 9;343(19):1350-4
pubmed: 11070098
Epigenomics. 2016 Mar;8(3):389-99
pubmed: 26673039
Neuro Oncol. 2021 Jun 1;23(6):865-866
pubmed: 33660766
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Cancers (Basel). 2021 Mar 08;13(5):
pubmed: 33800183
Neuropathol Appl Neurobiol. 2020 Aug;46(5):478-492
pubmed: 32072658
Curr Neurol Neurosci Rep. 2013 May;13(5):345
pubmed: 23532369
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
Neuro Oncol. 2021 Jun 1;23(6):955-966
pubmed: 33173941
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Br J Radiol. 2011 Dec;84 Spec No 1:S54-60
pubmed: 21427185
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Cancer Genet. 2012 Dec;205(12):613-21
pubmed: 23238284
CNS Oncol. 2016 Jul;5(3):145-57
pubmed: 27230974